SmartMetric (SMME) 10-K14 Oct 142014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Jun. 30, 2014	Sep. 08, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'SMME	'	'
Entity Common Stock, Shares Outstanding	'	167,707,937	'
Entity Registrant Name	'SmartMetric, Inc.	'	'
Entity Central Index Key	'0001301991	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$20,934,744

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
Current assets:	'	'
Cash	$97,924	$804,257
Prepaid expenses and other current assets	307,491	799,699
Total current assets	405,415	1,603,956
Other assets:	'	'
Advances to shareholder	22,478	0
Patent costs, less accumulated amortization of $14,625 and $13,125, respectively	375	1,875
Total assets	428,268	1,605,831
Current liabilities:	'	'
Accounts payable and accrued expenses	325,877	262,648
Liability for stock to be issued	355,750	216,978
Deferred Officer salary	125,015	61,681
Shareholder loan	0	21,572
Total current liabilities	806,642	562,879
Commitments and contingencies	'	'
Stockholders' (deficit) equity:	'	'
Preferred stock, $.001 par value; 5,000,000 shares authorized, 210,000 and 400,000 shares issued and outstanding	210	400
Common stock, $.001 par value; 200,000,000 shares authorized, 167,707,937 and 147,698,950 shares issued and outstanding , respectively	167,708	147,699
Additional paid-in capital	18,767,649	16,859,447
Accumulated deficit	-19,313,941	-15,964,594
Total stockholders' (deficit) equity	-378,374	1,042,952
Total liabilities and stockholders' (deficit) equity	$428,268	$1,605,831

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Accumulated amortization of patent costs (in dollars)	$14,625	$13,125
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	210,000	400,000
Preferred stock, shares outstanding	210,000	400,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	167,707,937	147,698,950
Common stock, shares outstanding	167,707,937	147,698,950

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
Consolidated Statements Of Operations (USD $)	Jun. 30, 2014	Jun. 30, 2013
Revenues	$0	$0
Expenses:	'	'
Officer's salary	190,000	197,500
Other general and administrative	2,669,693	3,354,798
Research and development	489,654	1,135,919
Total operating expenses	3,349,347	4,688,217
Loss from operations before income taxes	-3,349,347	-4,688,217
Income taxes	0	0
Net loss	($3,349,347)	($4,688,217)
Net loss per share, basic and diluted	($0.02)	($0.04)
Weighted average number of common shares outstanding, basic and diluted	161,252,272	130,120,074

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($3,349,347)	($4,688,217)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization	1,500	1,500
Common stock and warrants issued and issuable for services	1,057,755	2,824,387
Changes in assets and liabilities	'	'
(Increase) decrease in prepaid expenses and other current assets	492,208	-50,537
(Increase) decrease in advances to shareholder	-22,478	0
Increase (decrease) in accounts payable and accrued expenses	63,229	129,723
Increase (decrease) in deferred officer's salary	63,334	-5,345
Increase (decrease) in payroll taxes and related fees	0	-16,551
Net cash used in operating activities	-1,693,799	-1,805,040
CASH FLOWS FROM INVESTING ACTIVITIES	0	0
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Loans from related parties	0	20,150
Repayments of loans from related parties	-21,572	0
Proceeds from sale of common stock	870,266	2,406,972
Liability for stock to be issued	138,772	-707,414
Net cash provided by financing activities	987,466	1,719,708
NET (DECREASE) IN CASH	-706,333	-85,332
CASH BEGINNING OF YEAR	804,257	889,589
END OF YEAR	97,924	804,257
CASH PAID DURING THE YEAR FOR:	'	'
Income taxes	0	0
Interest	0	0
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES	'	'
Issuance of preferred stock and reduction of additional paid in capital for patent	0	200
Series B Preferred Stock [Member]	'	'
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES	'	'
Common Stock	$190	$0

Consolidated_Statements_of_Cha

Consolidated Statements of Changes In Stockholders' Equity (Deficit) (USD $)	Total	Preferred Stock [Member]	Common Stock Class A [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]
Balance at Jun. 30, 2012	$499,810	$200	$0	$118,975	$11,657,012	($11,276,377)
Balance, (in Shares) at Jun. 30, 2012	'	200,000	0	118,974,672	'	'
Shares issued for patent	0	200	0	0	-200	0
Shares issued for patent (in shares)	'	200,000	0	0	'	'
Shares issued of common stock and warrants for services rendered	2,793,136	0	0	13,345	2,779,791	0
Shares issued of common stock and warrants for services rendered (in shares)	'	0	0	13,344,760	'	'
Shares issued of common stock and warrants for cash	2,438,223	0	0	15,379	2,422,844	0
Shares issued of common stock and warrants for cash (in shares)	'	0	0	15,379,518	'	'
Net loss for the year	-4,688,217	0	0	0	0	-4,688,217
Balance at Jun. 30, 2013	1,042,952	400	0	147,699	16,859,447	-15,964,594
Balance, (in shares) at Jun. 30, 2013	'	400,000	0	147,698,950	'	'
Shares issued upon conversion of preferred stock	0	-190	0	9,500	-9,310	0
Shares issued upon conversion of preferred stock (in shares)	'	-190,000	0	9,500,000	'	'
Shares issued of common stock and warrants for services rendered	1,183,620	0	0	6,015	1,177,605	0
Shares issued of common stock and warrants for services rendered (in shares)	'	0	0	6,014,821	'	'
Shares issued of common stock and warrants for cash	744,401	0	0	4,494	739,907	0
Shares issued of common stock and warrants for cash (in shares)	'	0	0	4,494,166	'	'
Net loss for the year	-3,349,347	0	0	0	0	-3,349,347
Balance at Jun. 30, 2014	($378,374)	$210	$0	$167,708	$18,767,649	($19,313,941)
Balance, (in shares) at Jun. 30, 2014	'	210,000	0	167,707,937	'	'

ORGANIZATION_AND_BASIS_OF_PRES

ORGANIZATION AND BASIS OF PRESENTATION	12 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Jun. 30, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
ORGANIZATION AND BASIS OF PRESENTATION	'
	NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION

	SmartMetric, Inc. (the “Company” or “SmartMetric”) was incorporated in the State of Nevada on December 18, 2002. SmartMetric’s main product is a fingerprint sensor-activated card with a finger sensor onboard the card and a built-in rechargeable battery for portable biometric identification. This card may be referred to as a biometric card or the SmartMetric Biometric Datacard. SmartMetric has completed development of its card along with pre mass manufacturing cards but has not yet begun to mass manufacture the biometric fingerprint activated cards.

	Going Concern

	As shown in the accompanying consolidated financial statements the Company has incurred recurring losses of $3,349,347 and $4,688,217 for the years ended June 30, 2014 and 2013 respectively, and has incurred a cumulative loss of $19,313,941 since inception (December 18, 2002). The Company is currently in the development stage and has spent a substantial portion of its time in the development of its technology.

	There is no guarantee that the Company will be able to raise enough capital or generate revenues to sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

	Management believes that the Company’s capital requirements will depend on many factors. These factors include the final phase of development and mass production being successful as well as product implementation and distribution.

	The consolidated financial statements do not include any adjustments relating to the carrying amounts of recorded assets or the carrying amounts and classification of recorded liabilities that may be required should the Company be unable to continue as a going concern.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2014
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	Development Stage Company

	The Company is considered to be in the development stage as defined in ASC 915-10, "Accounting and Reporting by Development Stage Enterprises". The Company has devoted substantially all of its efforts to the development of its technology. Additionally, the Company has allocated a substantial portion of its time and investment in bringing its services to the market, and the raising of capital.

	Principles of Consolidation

	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, SmartMetric Australia Pty. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to income taxes and contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

	Cash and Cash Equivalents

	The Company considers all highly liquid debt instruments and other short-term investments with an initial maturity of three months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits exposes the Company to cash concentration risk. The Company had no cash equivalents at June 30, 2014 and 2013.

	Fair Value of Financial Instruments

	The carrying amounts reported in the consolidated balance sheet for cash, accounts payable, and accrued expenses including payroll withholdings, interest and penalties approximate fair value because of the immediate or short-term maturity of these financial instruments.

	ASC 820 defines fair value, provides a consistent framework for measuring fair value under generally accepted accounting principles and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

	Level 1inputs: Quoted prices for identical instruments in active markets.

	Level 2 inputs: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

	Level 3 inputs: Instruments with primarily unobservable value drivers.

	Research and Development

	The Company annually incurs costs on activities that relate to research and development of new technology and products. Research and development costs are expensed as incurred.

	Revenue Recognition

	The Company has not recognized revenues to date. The Company anticipates recognizing revenue in accordance with the contracts it enters into for the sale and distribution of its products.

	Accounts Receivable

	The Company will extend credit based on its evaluation of the customers’ financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company will monitor exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The Company has not recorded any receivables, and therefore no allowance for doubtful accounts.

	Uncertainty in Income Taxes

	GAAP requires the recognition and measurement of uncertain income tax positions using a “more-likely-than-not” approach. Management evaluates Company tax positions on an annual basis and has determined that as of June 30, 2014 no accrual for uncertain income tax positions is necessary.

	Advertising Costs

	The Company will expense the cost associated with advertising as incurred.

	Equipment

	Equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated economic useful lives of the assets ranging from 3 - 5 years.

	Impairment of Long-Lived Assets

	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company does not perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

	Loss Per Share of Common Stock

	Basic net loss per common share is computed using the weighted average number of common shares outstanding. The calculation of diluted earnings per share ("EPS") includes consideration of dilution arising from common stock equivalents, such as stock issuable pursuant to the exercise of stock options and warrants. Common stock equivalents were not included in the computation of diluted earnings per share on the consolidated statement of operations due to the fact that the Company reported a net loss and to do so would be anti-dilutive for the periods presented.

	Stock-Based Compensation

The Company measures expense for issuances of stock-based compensation to employees and others at fair value of the stock and warrants issued, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance obligation is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital.

Reclassifications

Certain amounts in the 2013 consolidated financial statements have been reclassified for comparative purposes to conform to the presentation in the current year consolidated financial statements. These reclassifications had no effect on previously reported results.

Recent Accounting Pronouncements

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the annual period ended June 30, 2014, and accordingly, is no longer presenting the inception-to-date financial information and disclosures formerly required.

PREPAID_EXPENSES

PREPAID EXPENSES	12 Months Ended
PREPAID EXPENSES	Jun. 30, 2014
Prepaid Expenses [Abstract]	'
PREPAID EXPENSES	'
	NOTE 3 - PREPAID EXPENSES

	Prepaid expenses represent the unexpired terms of various consulting agreements and expire through November 2014. These consulting agreements were entered into for the issuance of common stock and warrants and were valued based on the stock price or computed warrant value at the time of the respective agreement.

PATENT_COSTS

PATENT COSTS	12 Months Ended
PATENT COSTS	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
PATENT COSTS	'
	NOTE 4 - PATENT COSTS

	Patent costs as of June 30, 2014 and June 30, 2013 are summarized as follows:

		Estimated
		Useful Lives		June 30,		June 30,
		( Years)		2014		2013

	Legal fees paid in connection with patent Applications		10	$	15,000	$	15,000

	Less: accumulated amortization				-14,625		-13,125
	Patent costs, net			$	375	$	1,875

	Amortization expense was $1,500 for the years ended June 30, 2014 and 2013, respectively.

COMMITMENTS

COMMITMENTS	12 Months Ended
COMMITMENTS	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS	'
	NOTE 5 - COMMITMENTS

	Patent License Agreement

	Effective August 1, 2004, the Company executed a license agreement with Applied Cryptography, Inc. (“ACI”), a corporation controlled by the Company’s president and the owner of certain technology. Pursuant to the license agreement, the Company has the right to make use of this technology for the purpose of developing software and systems to be used by the Company to provide any or all of the following: 1) secure transactions over the Internet from home and office computers; 2) an automatic method for connecting to remote computers; 3) a method of developing targeted advertising to home and/or office computers; and 4) identity verification and access control as provided for in the patent. Pursuant to this license agreement, ACI is to receive 2% of all revenues generated by the Company on products which utilize this patented technology. The license fee is to be paid within 45 days of the end of each quarter. In the event no revenues are generated through the use of any of the licensed patents during a given quarter, no money shall be owed ACI for such quarter. ACI has the right to rescind the license agreement and reclaim all rights and interest in the patents if certain events, such as the Company’s filing for bankruptcy protection or reorganization, occur. The license agreement remains in effect for the lives of the patents. The Company may utilize the technological applications anywhere in the world without limitation. Upon execution of the Assignment and Assumption Agreement on December 11, 2009 (see Note 6), the Patent License Agreement was terminated.

	During November 2012, the Company acquired license rights to ACI's Medical Keyring Device technology in consideration of the Company's issuance to ACI of 200,000 shares of its Series B Convertible Preferred Stock.

	During September 2013, the Company acquired license rights to ACI's BioCentric Cloud Device technology in consideration of the Company's obligation to issue to ACI of 200,000 shares of its Series B Convertible Preferred Stock. As of the filing date, the Company has not increased its amount of Series B Convertible Preferred Stock shares and, accordingly, these shares have not been issued.

	Lease Agreement

	In February 2012, the company entered into a facilities lease in Buenos Aires, Argentina for its manufacturing activities. The lease term is from March 1, 2012 through January 31, 2015. The Company exited its Argentina offices in February of 2014. The Company also utilizes offices in Australia, Israel and Las Vegas, Nevada. The Company’s main office is located in Las Vegas, Nevada. Rent expense under all leases for the years ended June 30, 2014 and 2013 was $59,635 and $103,814 respectively.

	Related Party Transactions

	The Company has made cash advances to its Chief Executive Officer with an aggregate amount due of $22,478 and $0 as of June 30, 2014 and June 30, 2013, respectively. The Company’s Chief Executive Officer has made cash advances to the Company with an aggregate amount due of $0 and $21,572 as of June 30, 2014 and 2013, respectively. These advances bear interest at 5.00% per annum.

	As of June 30, 2014 and June 30, 2013, the Company has accrued the amounts of $125,015 and $61,681, respectively, as deferred Officer’s salary for the difference between the president’s annual salary and the amounts paid.

STOCKHOLDERS_EQUITY_DEFICIT

STOCKHOLDERS' EQUITY (DEFICIT)	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY (DEFICIT)	'
	NOTE 6 - STOCKHOLDERS’ EQUITY (DEFICIT)

	Preferred Stock

	As of June 30, 2014, the Company has 5,000,000 shares of preferred stock, par value $0.001, authorized and 210,000 shares issued and outstanding.

	On December 11, 2009, the Company filed a Certificate of Designation with the State of Nevada, to designate 500,000 shares of the preferred stock to be designated as Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock”).

	Each share of Series B Convertible Preferred Stock has a par value of $0.001, and a stated value equal to $5.00 (“Stated Value”). Holders of the Series B Convertible Preferred Stock are entitled to receive dividends or other distributions with the holders of the common stock of the Company on an as converted basis when, as, and if declared by the directors of the Company. Holders of the Series B Convertible Preferred Stock are entitled to convert all or any one (1) share of the Series B Convertible Preferred Stock into fifty (50) shares of common stock.

	Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (“liquidation”), holders of the Series B Convertible Preferred Stock are entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the Stated Value, pro rata with the holders of the common stock.

	On December 11, 2009, the Company entered into an Assignment and Assumption Agreement with ACI (the “assignment and Assumption Agreement”). In accordance with the Assignment and Assumption Agreement, ACI conveyed, assigned and transferred to the Company all of ACI’s rights, title and interest in and to the Patent (see Note 5) and delegated to the Company all of its duties and obligations to be performed under the Patent; and the Company hereby accepts the assignment of all of ACI’s rights, title and interest to the Patent and the rights and delegation of duties and obligations and agrees to be bound by and to assume such duties and obligations.

	In consideration for the assignment of the Patent, the Company issued 200,000 shares of Series B Convertible Preferred Stock. ACI may only convert these shares into common shares (in accordance with the conversion terms noted herein) upon delivering to the Company, a third party valuation of the assigned Patent conducted by a nationally qualified accounting firm or IP law firm mutually agreed upon between the Company and ACI, indicating that such Patent is valued at a minimum of $1,000,000.

	On November 12, 2012, the Company issued 200,000 shares of its Series B Convertible Preferred Stock to ACI in consideration for ACI’s patent relating to the Medical Keyring Device.

	In July 2013, ACI elected to convert 190,000 shares of Series B Convertible Preferred Stock, issued in 2012, into 9,500,000 shares of the Company’s common stock.

	During September 2013, the Company acquired license rights to ACI's BioCentric Cloud Device technology in consideration of the Company's obligation to issue to ACI of 200,000 shares of its Series B Convertible Preferred Stock. As of the filing date, the Company has not increased its amount of Series B Convertible Preferred Stock shares and, accordingly, these shares have not been issued.

	Common Stock (Continued)

	In accordance with Staff Accounting Bulletin (“SAB”) topic 5G “Transfers of Non-monetary Assets by Promoters and Shareholders” the Company recorded these transactions at ACI’s carrying basis of the Patents, which was $0.

	Class A Common Stock

	As of June 30, 2014, the Company has 50,000,000 shares of Class A common stock, par value $0.001, authorized and no shares issued and outstanding. In October 2003, the Company issued 50,000,000 shares of Class A common stock at par value ($50,000). These shares were converted into 50,000,000 shares of common stock in 2006.

	Common Stock

	The Company was incorporated on December 18, 2002, with 45,000,000 shares of Common Stock, par value $0.001. The articles of incorporation were amended in 2006 to increase the number of authorized shares to 100,000,000 shares, and again in 2009 to increase the number of authorized shares to 200,000,000.

	As of June 30, 2014, the Company has 167,707,937 shares of common stock issued and outstanding.

	During the three months ended September 30, 2012, the Company sold 860,000 shares and twelve month warrants to purchase an additional 860,000 shares at $0.80 per share for net proceeds of $171,758.

	During the three months ended September 30, 2012, the Company authorized the issuance of 4,379,122 shares for legal and consulting services valued at $627,899.

	During the three months ended December 31, 2012, the Company sold for cash 200,000 shares and twelve month warrants to purchase an additional 200,000 shares at $0.80 per share. The Company also sold for cash 125,000 shares and twelve month warrants to purchase an additional 125,000 shares at $0.50 per share. Total net proceeds received was $60,041.

	During the three months ended December 31, 2012, the Company authorized the issuance of 5,575,000 shares for consulting services valued at $1,115,000.

	During the three months ended March 31, 2013, the Company sold for cash 4,131,328 shares and twelve month warrants to purchase an additional 4,131,328 shares at $0.50 per share for net proceeds of $672,380.

	During the three months ended June 30, 2013, the Company sold for cash 10,097,331 shares and twelve month warrants to purchase an additional 10,097,331 shares at $0.50 per share for net proceeds of $1,499,793.

	During the three months ended September 30, 2013, the Company sold for cash 515,367 shares and twenty-four month warrants to purchase an additional 515,367 shares at $0.70 per share for net proceeds of $123,474.

	During the three months ended September 30, 2013, the Company issued 130,875 shares for consulting services valued at $70,898, based on the stock price at the time of the respective agreements underlying the services provided.

	During the three months ended December 31, 2013, the Company issued 2,134,166 shares for consulting services valued at $339,900, based on the stock price at the time of the respective agreements underlying the services provided.

	During the three months ended December 31, 2013, the Company sold for cash 660,000 shares and twenty-four month warrants to purchase an additional 660,000 shares at $0.60 per share for net proceeds of $118,700.

	During the three months ended March 31, 2014, the Company sold for cash 2,120,000 shares and twenty-four month warrants to purchase: (i) 4,240,000 shares at $0.70 per share, and (ii) 2,136,960 shares at $1.00 per share, for net proceeds of $338,687.

	During the three months ended March 31, 2014, the Company issued 2,798,776 shares for consulting and legal services valued at $375,149, based on the stock price at the time of the respective agreements underlying the services provided.

	During the three months ended June 30, 2014, the Company sold for cash 1,812,500 shares and twenty-four month warrants to purchase: (i) 3,625,000 shares at $0.70 per share, and (ii) 1,827,000 shares at $1.00 per share, for net proceeds of $289,405.

	During the three months ended June 30, 2014, the Company issued 1,490,170 shares for consulting and legal services value at $205,192, based on the stock price at the time of the respective agreements underlying the services provided.

Warrants

From time to time the Company granted warrants in connection with private placements of securities, as described herein.

In October 2009, the Company executed a warrant agreement with an investor relations company for 5,000,000 warrants to be issued in two tranches. The first tranche of 2,500,000 warrants (the “October warrants”) has been issued in October 2009, and the second tranche of 2,500,000 warrants has been issued on March 31, 2010 (the “March warrants”). The October warrants, which were set to expire October 25, 2014(as extended) but have been further extended by the Company to expire on October 25, 2015, have strike prices as follows: 1,000,000 at $0.10 per share; 1,000,000 at $0.15 per share; and 500,000 at $0.20 per share. The March warrants, which were set to expire March 29, 2015 (as extended) but have been further extended by the Company to expire on March 29, 2016, have strike prices as follows: 500,000 at $0.20 per share; 1,000,000 at $0.25 per share; and 1,000,000 at $0.30 per share.

In June 2011, the Company issued warrants to purchase 1,000,000 shares of its common stock at an exercise price of $0.50 per share as partial consideration for a consulting agreement. These warrants were set to expire on June 3, 2014 (as extended) but have been further extended by the Company to expire on June 3, 2015.

In connection with the extension of the above referenced warrants during the year ended June 30, 2014, which were partial consideration in connection with a new consulting agreement, the Company assigned a value of $209,300 using the Black-Scholes option pricing model. The Company is recording the charge to consulting expenses over the term of the new consulting agreement. During the year ended June 30, 2014, the Company recorded $174,417 to consulting expenses, included as a component of other general and administrative expenses.

In May 2012, the Company issued warrants to purchase 250,000 shares of its common stock at an exercise price of $0.50 per share, as partial consideration for a consulting agreement for public relations services. The warrants expired in May 2014.

As of June 30, 2014 and June 30, 2013, the following is a breakdown of the activity:

June 30, 2014:

Outstanding - beginning of year		21,757,578
Issued		13,004,326
Exercised		-
Expired		-15,757,578

Outstanding - end of year		19,004,326

June 30, 2013:

Outstanding - beginning of year		18,802,820
Issued		16,507,578
Exercised		-
Expired		-13,552,820

Outstanding - end of year		21,757,578

At June 30, 2014, all of the 19,004,326 warrants are vested and 13,004,326 warrants expire at various times through June 30, 2016, 1 million warrants expire on June 20, 2015, 2.5 million warrants expire on October 25, 2015, and 2.5 million warrants expire on March 29, 2016.

INCOME_TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 7 - INCOME TAXES

	Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. The Company recognizes interest and penalties related to income tax matters as a component of income tax expense.

	At June 30, 2014 and 2013, deferred tax assets consist of the following:

		2014			2013
	Net operating loss carryforward	$	5,541,413		$	4,495,399
	Warrant issuances		240,966			171,374
	Other		44,137			22,604
	Valuation allowance		-5,826,516			-4,689,377
		$	-		$	-

	A reconciliation of the activity related to the liability for gross unrecognized tax benefits during fiscal 2014 and 2013 is as follows:

		Year ended June 30,
		2014			2013
	Balance as of beginning of fiscal year	$	164,869		$	164,869
	Increases related to prior year positions		-			-
	Balance as of June 30,	$	164,869		$	164,869

	At June 30, 2014, the Company had a net operating loss carryforwards in the amount of $16,298,273 available to offset future taxable income through 2033, which will begin to expire in 2022. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. A reconciliation of the Company’s effective tax rate as a percentage of income before taxes and federal statutory rate for the period ended June 30, 2014 and 2013 is summarized as follows:

		2014				2013
	Tax on income before income tax		34	%			34	%
	Effect of nontemporary differences		-0.06	%			-0.66	%
	Effect of NOL true-up adjustment		0	%			-14.48	%
	Change in valuation allowance		-33.94	%			-18.86	%
			0	%			0	%

	The total amount of unrecognized tax benefits can change due to tax examination activities, lapse of applicable statutes of limitations and the recognition and measurement criteria under the guidance related to accounting for uncertainty in income taxes. The Company does not believe any significant increases or decreases will occur within the next twelve months.

	The Company files income tax returns in the United States ("U.S.") federal jurisdiction. Generally, the Company is no longer subject to U.S. federal examinations by tax authorities for fiscal years prior to 2010. The Company does not file in any other jurisdiction and remains open for audit for all tax years as the statute of limitations does not begin until the returns are filed.

LITIGATION

LITIGATION	12 Months Ended
LITIGATION	Jun. 30, 2014
Litigation [Abstract]	'
LITIGATION	'
	NOTE 8 - LITIGATION

	On September 12, 2014, the Company filed an appeal before the full bench of the Federal Circuit Court in Washington D.C. in respect of an appeal of a prior ruling of non infringement on the part of the defendants Visa Inc. and MasterCard International by the Federal District Court for the Central District of California in the last quarter of the calendar year ending December 31, 2013.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2014
Development Stage Company	'
	Development Stage Company

	The Company is considered to be in the development stage as defined in ASC 915-10, "Accounting and Reporting by Development Stage Enterprises". The Company has devoted substantially all of its efforts to the development of its technology. Additionally, the Company has allocated a substantial portion of its time and investment in bringing its services to the market, and the raising of capital.

Principles of Consolidation	'
	Principles of Consolidation

	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, SmartMetric Australia Pty. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates	'
	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to income taxes and contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Cash and Cash Equivalents	'
	Cash and Cash Equivalents

	The Company considers all highly liquid debt instruments and other short-term investments with an initial maturity of three months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits exposes the Company to cash concentration risk. The Company had no cash equivalents at June 30, 2014 and 2013.

Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments

	The carrying amounts reported in the consolidated balance sheet for cash, accounts payable, and accrued expenses including payroll withholdings, interest and penalties approximate fair value because of the immediate or short-term maturity of these financial instruments.

	ASC 820 defines fair value, provides a consistent framework for measuring fair value under generally accepted accounting principles and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

	Level 1inputs: Quoted prices for identical instruments in active markets.

	Level 2 inputs: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

	Level 3 inputs: Instruments with primarily unobservable value drivers.

Research and Development	'
	Research and Development

	The Company annually incurs costs on activities that relate to research and development of new technology and products. Research and development costs are expensed as incurred.

Revenue Recognition	'
	Revenue Recognition

	The Company has not recognized revenues to date. The Company anticipates recognizing revenue in accordance with the contracts it enters into for the sale and distribution of its products.

Accounts Receivable	'
	Accounts Receivable

	The Company will extend credit based on its evaluation of the customers’ financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company will monitor exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The Company has not recorded any receivables, and therefore no allowance for doubtful accounts.

Uncertainty in Income Taxes	'
	Uncertainty in Income Taxes

	GAAP requires the recognition and measurement of uncertain income tax positions using a “more-likely-than-not” approach. Management evaluates Company tax positions on an annual basis and has determined that as of June 30, 2014 no accrual for uncertain income tax positions is necessary.

Advertising Costs	'
	Advertising Costs

	The Company will expense the cost associated with advertising as incurred.

Equipment	'
	Equipment

	Equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated economic useful lives of the assets ranging from 3 - 5 years.

Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets

	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company does not perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Loss Per Share of Common Stock	'
	Loss Per Share of Common Stock

	Basic net loss per common share is computed using the weighted average number of common shares outstanding. The calculation of diluted earnings per share ("EPS") includes consideration of dilution arising from common stock equivalents, such as stock issuable pursuant to the exercise of stock options and warrants. Common stock equivalents were not included in the computation of diluted earnings per share on the consolidated statement of operations due to the fact that the Company reported a net loss and to do so would be anti-dilutive for the periods presented.

Stock-Based Compensation	'
	Stock-Based Compensation

	The Company measures expense for issuances of stock-based compensation to employees and others at fair value of the stock and warrants issued, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance obligation is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital.

Reclassifications	'
	Reclassifications

	Certain amounts in the 2013 consolidated financial statements have been reclassified for comparative purposes to conform to the presentation in the current year consolidated financial statements. These reclassifications had no effect on previously reported results.

Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements

	On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the annual period ended June 30, 2014, and accordingly, is no longer presenting the inception-to-date financial information and disclosures formerly required.

PATENT_COSTS_Tables

PATENT COSTS (Tables)	12 Months Ended
PATENT COSTS (Tables)	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets	'
	Patent costs as of June 30, 2014 and June 30, 2013 are summarized as follows:

		Estimated
		Useful Lives		June 30,		June 30,
		( Years)		2014		2013

	Legal fees paid in connection with patent Applications		10	$	15,000	$	15,000

	Less: accumulated amortization				-14,625		-13,125
	Patent costs, net			$	375	$	1,875

STOCKHOLDERS_EQUITY_DEFICIT_Ta

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	12 Months Ended
STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule Of Share Based Compensation Warrant Activity	'
	As of June 30, 2014 and June 30, 2013, the following is a breakdown of the activity:

	June 30, 2014:

	Outstanding - beginning of year	21,757,578
	Issued	13,004,326
	Exercised	-
	Expired	-15,757,578

	Outstanding - end of year	19,004,326

	June 30, 2013:

	Outstanding - beginning of year	18,802,820
	Issued	16,507,578
	Exercised	-
	Expired	-13,552,820

	Outstanding - end of year	21,757,578

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities	'
	At June 30, 2014 and 2013, deferred tax assets consist of the following:

		2014			2013
	Net operating loss carryforward	$	5,541,413		$	4,495,399
	Warrant issuances		240,966			171,374
	Other		44,137			22,604
	Valuation allowance		-5,826,516			-4,689,377
		$	-		$	-

Schedule of Unrecognized Tax Benefits Roll Forward	'
	A reconciliation of the activity related to the liability for gross unrecognized tax benefits during fiscal 2014 and 2013 is as follows:

		Year ended June 30,
		2014			2013
	Balance as of beginning of fiscal year	$	164,869		$	164,869
	Increases related to prior year positions		-			-
	Balance as of June 30,	$	164,869		$	164,869

Schedule of Effective Income Tax Rate Reconciliation	'
	A reconciliation of the Company’s effective tax rate as a percentage of income before taxes and federal statutory rate for the period ended June 30, 2014 and 2013 is summarized as follows:

		2014				2013
	Tax on income before income tax		34	%			34	%
	Effect of nontemporary differences		-0.06	%			-0.66	%
	Effect of NOL true-up adjustment		0	%			-14.48	%
	Change in valuation allowance		-33.94	%			-18.86	%
			0	%			0	%

ORGANIZATION_AND_BASIS_OF_PRES1

ORGANIZATION AND BASIS OF PRESENTATION (Details Textual) (USD $)	12 Months Ended		138 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Net Income (Loss) Attributable To Parent	($3,349,347)	($4,688,217)	$19,313,941

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	12 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment, Depreciation Methods	'straight-line method
Minimum [Member]	'
Property, Plant and Equipment, Useful Life	'3 years
Maximum [Member]	'
Property, Plant and Equipment, Useful Life	'5 years

PATENT_COSTS_Details

PATENT COSTS (Details) (USD $)	12 Months Ended
PATENT COSTS (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Legal fees paid in connection with patent Applications	$15,000	$15,000
Less: accumulated amortization	-14,625	-13,125
Patent costs, net	$375	$1,875
Estimated Useful Lives (Years)	'10 years	'

PATENT_COSTS_Details_Textual

PATENT COSTS (Details Textual) (USD $)	12 Months Ended
PATENT COSTS (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization	$1,500	$1,500
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization	$1,500	$1,500

COMMITMENTS_Details_Textual

COMMITMENTS (Details Textual) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Sep. 30, 2013

Nov. 12, 2012

Dec. 11, 2009

Sep. 30, 2013

Series B Convertible Preferred Stock [Member]

Applied Cryptography, Inc [Member]

Series B Convertible Preferred Stock [Member]

Other Commitments [Line Items]

License Agreement Initiation Date

1-Aug-04

Percentage Of Revenue To Be Paid As License Fee

2.00%

License Fee Periodic Payment Description

'The license fee is to be paid within 45 days of the end of each quarter

Lease Agreement Initiation Date

'February 2012

Lease Initiation Date

1-Mar-12

Lease Expiration Date

31-Jan-15

Operating Leases, Rent Expense

$59,635

$103,814

Due to Related Parties

21,572

Related Party Transaction, Rate

5.00%

Deferred Compensation Liability, Current

125,015

61,681

125,015

61,681

Stock Issued During Period, Shares, New Issues

1,812,500

2,120,000

660,000

515,367

10,097,331

4,131,328

860,000

200,000

Due from Related Parties, Current

$22,478

STOCKHOLDERS_EQUITY_DEFICIT_De

STOCKHOLDERS' EQUITY (DEFICIT) (Details) (Warrant [Member])	1 Months Ended		12 Months Ended
STOCKHOLDERS' EQUITY (DEFICIT) (Details) (Warrant [Member])	Mar. 31, 2010	Oct. 31, 2009	Jun. 30, 2014	Jun. 30, 2013
Warrant [Member]	'	'	'	'
Outstanding - beginning of year	'	'	21,757,578	18,802,820
Issued	2,500,000	2,500,000	13,004,326	16,507,578
Exercised	'	'	0	0
Expired	'	'	-15,757,578	-13,552,820
Outstanding - end of year	'	5,000,000	19,004,326	21,757,578

STOCKHOLDERS_EQUITY_DEFICIT_De1

STOCKHOLDERS' EQUITY (DEFICIT) (Details Textual) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

31-May-12

Jun. 30, 2011

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2010

Oct. 31, 2009

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Oct. 31, 2009

Mar. 31, 2010

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Dec. 11, 2009

Sep. 30, 2013

Jul. 31, 2013

Jun. 30, 2014

Nov. 12, 2012

Dec. 11, 2009

Sep. 30, 2013

Oct. 31, 2003

Jun. 30, 2014

Jul. 31, 2013

Jun. 30, 2006

Dec. 18, 2012

Jun. 30, 2009

Sep. 30, 2012

Legal and Consultancy Services [Member]

Issue One [Member]

Issue Two [Member]

Warrant [Member]

October Warrant One 2009 [Member]

October Warrant Two 2009 [Member]

October Warrant Three 2009 [Member]

March Warrant One 2010 [Member]

March Warrant Two 2010 [Member]

March Warrant Three 2010 [Member]

Twelve Month Warrants [Member]

Preferred Stock [Member]

Twenty Four Months Warrant [Member]

Twenty Four Months Warrant One [Member]

Twenty Four Months Warrant Two [Member]

Expire on June 30 2016 [Member]

Expire on June 20 2015 [Member]

Expire on October 25 2015 [Member]

Expire on March 29 2016 [Member]

Series B Convertible Preferred Stock [Member]

Common Class [Member]

Common Stock [Member]

Issue One [Member]

Issue Two [Member]

Applied Cryptography, Inc [Member]

Legal and Consultancy Services [Member]

Preferred stock, shares authorized

5,000,000

500,000

Preferred Stock, Par Value Per Share

$0.00

Preferred Stock, Stated Value Per Share

Preferred stock, shares issued

210,000

400,000

210,000

400,000

Preferred Stock, Shares Outstanding

210,000

400,000

210,000

400,000

210,000

Conversion of Stock, Description

'Holders of the Series B Convertible Preferred Stock are entitled to convert all or any one (1) share of the Series B Convertible Preferred Stock into fifty (50) shares of common stock.

Stock Issued During Period, Shares, New Issues

1,812,500

2,120,000

660,000

515,367

10,097,331

4,131,328

860,000

200,000

125,000

200,000

50,000,000

Stock Issued During Period, Value, New Issues

$744,401

$2,438,223

$209,300

$1,000,000

Common stock, shares authorized

200,000,000

50,000,000

100,000,000

45,000,000

200,000,000

Common Stock, Par Or Stated Value Per Share

$0.00

$50,000

$0.00

Common stock, shares issued

167,707,937

147,698,950

167,707,937

147,698,950

Common stock, shares outstanding

167,707,937

147,698,950

167,707,937

147,698,950

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

250,000

1,000,000

10,097,331

4,131,328

860,000

200,000

125,000

660,000

515,367

3,625,000

4,240,000

1,827,000

2,136,960

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.50

$0.80

$0.50

$0.60

$0.70

Proceeds from sale of common stock

289,405

338,687

118,700

123,474

1,499,793

672,380

60,041

171,758

870,266

2,406,972

Stock Issued During Period, Shares, Issued for Services

5,575,000

1,490,170

2,798,776

2,134,166

130,875

4,379,122

Stock Issued During Period, Value, Issued for Services

1,115,000

205,192

375,149

339,900

70,898

627,899

Number Of Warrants To Be Expired

13,004,326

1,000,000

2,500,000

Conversion Of Preferred Stock Into Common Stock

-190,000

190,000

9,500,000

50,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

5,000,000

19,004,326

21,757,578

18,802,820

1,000,000

500,000

1,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

2,500,000

13,004,326

16,507,578

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

$0.10

$0.15

$0.20

$0.25

$0.30

Legal Fees

$174,417

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

19,004,326

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Net operating loss carryforward	$5,541,413	$4,495,399
Warrant issuances	240,966	171,374
Other	44,137	22,604
Valuation allowance	-5,826,516	-4,689,377
Deferred Tax Assets, Net	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
INCOME TAXES (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Balance as of beginning of fiscal year	$164,869	$164,869
Increases related to prior year positions	0	0
Balance as of June 30,	$164,869	$164,869

INCOME_TAXES_Details_2

INCOME TAXES (Details 2)	12 Months Ended
INCOME TAXES (Details 2)	Jun. 30, 2014	Jun. 30, 2013
Tax on income before income tax	34.00%	34.00%
Effect of nontemporary differences	-0.06%	-0.66%
Effect of NOL true-up adjustment	0.00%	-14.48%
Change in valuation allowance	-33.94%	-18.86%
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
INCOME TAXES (Details Textual) (USD $)	Jun. 30, 2014
Operating Loss Carryforwards	$16,298,273
Operating Loss Carryforwards, Limitations on Use	'available to offset future taxable income through 2033, which will begin to expire in 2022.